Study on timing cancer treatments to the morning comes under fire
Angus Chen covers all issues broadly related to cancer including drugs, policy, science, and equity. He joined STAT…
Key study of Grail’s cancer detection test fails in setback for company
Angus Chen covers all issues broadly related to cancer including drugs, policy, science, and equity. He joined STAT…
FDA taps AI executive to lead digital health center
Mario Aguilar covers technology in health care, including artificial intelligence, virtual reality, wearable devices, telehealth, and digital therapeutics.…
FDA’s Høeg plans to scrutinize SSRIs, RSV shots for babies
WASHINGTON — Tracy Beth Høeg, the top drug regulator at the Food and Drug Administration, indicated in her…
We’re reading about China’s GLP-1 drugs, a puzzling FDA rejection
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and rewarding…
Ocular Therapeutix wet AMD drug Axpaxli tops Eylea in study
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…
As Health insurers embrace AI, providers say it undermines trust
Casey Ross covers the use of artificial intelligence in medicine and its underlying questions of safety, fairness, and…
Consumer group presses U.S. to authorize generic GLP-1s
Public Citizen petitioned the Trump administration to use a federal law to authorize generic competitors for GLP-1 drugs…
FDA rejects drug from Disc Medicine, early recipient of commissioner’s voucher
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…
Moderna’s president weighs in on FDA’s decision not to review its flu vaccine
Food and Drug Administration officials told Moderna in August that they would review its application for a new…